gci

Current Issue cover

Bayer and Azitra to Jointly Identify Bacteria Driving Acne, Dermatitis

Contact Author
Close
Fill out my online form.

Bayer AG and Azitra Inc. announced a joint agreement to collaborate in the identification and characterization of skin microbiome bacteria. 

See related: Inulin and Chicory Root Microbiome Care

The partnership will leverage Azitra’s proprietary panel of Staphylococcus epidermidis strains to identify potential candidates for the treatment of adverse skin conditions and diseases. Based on the results of the research partnership, Bayer plans to develop selected S. epidermidis strains for new natural skin care products under a future licensing agreement. Prospective areas of application include medicated skin care products for sensitive, eczema-prone skin as well as therapeutic products for skin diseases such as atopic dermatitis.

Regarding the arrangement, Richard Andrews, president and CEO of Azitra stated, “We are strongly committed to the potential of the microbiome to provide significant benefits for improved skin health and appearance, and by working together with Bayer, I am confident we can deliver on the promise of this technology.”

According to the companies, recent scientific publications suggest microorganisms in the skin microbiome can significantly contribute to the protection of the skin from hostile invasions. Additional positive effects include supporting the recovery from skin diseases such as atopic dermatitis, acne and rosacea; and may also accelerate wound healing.

“The skin microbiome offers a promising platform for the development and commercialization of natural skin care products that more and more people are looking for,” comments Heiko Schipper, member of the Board of Management of Bayer AG and president of Bayer Consumer Health. “As Bayer is committed to the development of science-based consumer health products through our own research as well as external partnerships, we’re delighted to collaborate with Azitra. The company has already demonstrated tolerability of a selected Staphylococcus epidermidis strain in healthy volunteers and is now planning to start the clinical demonstration of efficacy.”

Bayer will contribute to the research collaboration by providing suitable topical formulations that are able to maintain S. epidermidis viability while showing skin compatibility and sensorial performance. Azitra’s platform technology offers further screening options for beneficial strains appropriate for the treatment of dermatological diseases such as atopic dermatitis, acne or psoriasis. In addition, Bayer will review the use of Azitra’s genetically modified bacteria in dermatology and other consumer health areas, such as nutritional and digestive health.

"We [Azitra] are strongly committed to the potential of the microbiome to provide significant benefits for improved skin health and appearance and by working together with Bayer, I am confident we can deliver on the promise of this technology," states Andrews.

For more information, visit the Bayer AG or Azitra Inc. website.

Related Content